Cargando…

Analysis of serious adverse events in a pediatric community-acquired pneumonia randomized clinical trial in Malawi

Amoxicillin is recommended as first-line antibiotic treatment for community-acquired pneumonia, the leading infectious cause of mortality in children aged less than 5 years. We conducted a double-blind, randomized controlled non-inferiority trial comparing 3- to 5-day amoxicillin treatment for non-s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ginsburg, Amy Sarah, May, Susanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894403/ https://www.ncbi.nlm.nih.gov/pubmed/35241775 http://dx.doi.org/10.1038/s41598-022-07582-w

Ejemplares similares

Adherence to oral amoxicillin dispersible tablets in children with community-acquired pneumonia enrolled in clinical trials in Malawi
por: Ginsburg, Amy Sarah, et al.
Publicado: (2021)

Analysis of serious adverse events in a paediatric fast breathing pneumonia clinical trial in Malawi
por: Nkwopara, Evangelyn, et al.
Publicado: (2019)

Geographically linked risk factors for enrolment into a fast breathing child pneumonia trial in Lilongwe, Malawi: an Innovative Treatments in Pneumonia (ITIP) secondary analysis
por: Nkwopara, Evangelyn, et al.
Publicado: (2019)

Antibiotics for paediatric community-acquired pneumonia in resource-constrained settings
por: Ginsburg, Amy Sarah, et al.
Publicado: (2020)

Repeat assessment of examination signs among children in Malawi with fast-breathing pneumonia
por: Lenahan, Jennifer L., et al.
Publicado: (2020)

Serious adverse events of older adults in nursing home and community intervention trials
por: Datta, Rupak, et al.
Publicado: (2017)

Clinical Outcomes of Pneumonia and Other Comorbidities in Children Aged 2-59 Months in Lilongwe, Malawi: Protocol for the Prospective Observational Study “Innovative Treatments in Pneumonia”
por: Ginsburg, Amy Sarah, et al.
Publicado: (2019)

Etiology and Risk Factors for Mortality in an Adult Community-acquired Pneumonia Cohort in Malawi
por: Aston, Stephen J., et al.
Publicado: (2019)

Title Correction: Clinical Outcomes of Pneumonia and Other Comorbidities in Children Aged 2-59 Months in Lilongwe, Malawi: Protocol for the Prospective Observational Study “Innovative Treatments in Pneumonia”
por: Ginsburg, Amy Sarah, et al.
Publicado: (2019)

Fast-breathing vs chest-indrawing childhood pneumonia: baseline characteristics
por: Ginsburg, Amy Sarah, et al.
Publicado: (2021)

Development of a prognostic risk score to aid antibiotic decision-making for children aged 2-59 months with World Health Organization fast breathing pneumonia in Malawi: An Innovative Treatments in Pneumonia (ITIP) secondary analysis
por: McCollum, Eric D., et al.
Publicado: (2019)

Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: Nivolumab-related serious/fatal adverse events
por: Zhao, Bin, et al.
Publicado: (2018)

Biomarkers in Pediatric Community-Acquired Pneumonia
por: Principi, Nicola, et al.
Publicado: (2017)

Serious Neurological Adverse Events of Ceftriaxone
por: Lacroix, Clémence, et al.
Publicado: (2021)

Methods for conducting a double-blind randomized controlled clinical trial of three days versus five days of amoxicillin dispersible tablets for chest indrawing childhood pneumonia among children two to 59 months of age in Lilongwe, Malawi: a study protocol
por: Ginsburg, Amy Sarah, et al.
Publicado: (2018)

Impact of rhinoviruses on pediatric community-acquired pneumonia
por: Esposito, Susanna, et al.
Publicado: (2011)

Chest radiography in children aged 2–59 months enrolled in the Innovative Treatments in Pneumonia (ITIP) project in Lilongwe Malawi: a secondary analysis
por: Mvalo, Tisungane, et al.
Publicado: (2022)

Identification of serious, unpredictable adverse events with tocilizumab
Publicado: (2020)

Vaccine trials with no serious adverse reactions – estimation of upper 95% confidence intervals for likelihood of such events
por: Grech, Victor, et al.
Publicado: (2022)

Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia
por: Chen, Yu-Chin, et al.
Publicado: (2020)

Serious Adverse Events Among SPRINT Trial Participants Taking Statins at Baseline
por: Huesch, Marco D.
Publicado: (2017)

Depression and anxiety in cancer patient enrolled in clinical trials with serious adverse events
por: Peng, Zhen, et al.
Publicado: (2023)

Adverse events and death in patients with community-acquired pneumonia in the emergency department of a major university hospital in Brazil
por: Machado, A, et al.
Publicado: (2005)

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
por: Fraiman, Joseph, et al.
Publicado: (2022)

Validating a novel index (SWAT-Bp) to predict mortality risk of community-acquired pneumonia in Malawi
por: Buss, Imogen M, et al.
Publicado: (2018)

Serious adverse events associated with yellow fever vaccine
por: de Menezes Martins, Reinaldo, et al.
Publicado: (2015)

Analysis of serious adverse event: Writing a narrative
por: Nambiar, Indu
Publicado: (2018)

Community‐Acquired Pneumonia and Risk of Cardiovascular Events in People Living With HIV
por: Zifodya, Jerry S., et al.
Publicado: (2020)

Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
por: Zhao, Bin, et al.
Publicado: (2019)

1091 Serotype Distribution of S. pneumoniae Community Acquired Pneumonia (CAP) in Adults in the Netherlands in the CAPiTA (Community-Acquired Pneumonia Immunization Trial In Adults) Study Period
por: Hollingsworth, Rosalind, et al.
Publicado: (2014)

Mycoplasma pneumoniae and Adenovirus Coinfection Cause Pediatric Severe Community-Acquired Pneumonia
por: Li, Fei, et al.
Publicado: (2022)

Estimated Burden of Serious Fungal Infections in Malawi
por: Kalua, Khumbo, et al.
Publicado: (2018)

A prediction rule for severe adverse events in all inpatients with community-acquired pneumonia: a multicenter observational study
por: Sakakibara, Toshihiro, et al.
Publicado: (2022)

Serious Adverse Events in Pediatric Procedural Sedation Before and After the Implementation of a Pre-Sedation Checklist
por: Librov, Simona, et al.
Publicado: (2020)

Association of Frailty Index with Clinical BPH Progression and Serious Adverse Events: the MTOPS Trial
por: Bauer, Scott, et al.
Publicado: (2021)

Prediction of delayed recovery from pediatric community-acquired pneumonia
por: Don, Massimiliano, et al.
Publicado: (2010)

Management of Community-Acquired Pneumonia in Pediatrics: Adherence to Clinical Guidelines
por: Tannous, Rim, et al.
Publicado: (2020)

Characteristics and etiology of hospitalized pediatric community-acquired pneumonia in Taiwan
por: Chi, Hsin, et al.
Publicado: (2020)

Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis
por: Yao, Yanhong, et al.
Publicado: (2021)

Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis
por: Awadzi, Kwablah
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_ppuh1ndhqpf0tvvt0qimfpsn14